1
Return

Dose, Interval, and Context: Interpreting SOS/VOD Risk after Inotuzumab before Second Allogeneic Transplantation

delete2026-06-17
delete0
PRE
AI
C
Curtis Marcoux *
P
Partow Kebriaei
DOI：10.1016/j.jtct.2026.06.018delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En

Journal

Transplantation and Cellular Therapy cover
Transplantation and Cellular Therapy
IF:
4.4
Papers:
2.1K
Citations:
4.4K

Organization

D
Dalhousie University
Scholars:
1.9W
Papers: 1.8W
Citations: 2.3W
M
md anderson cancer center
Scholars:
227
Papers: 102
Citations: 1
Cited Papers

Cited Papers

Citing Papers

Citing Papers